Actinium Pharmaceuticals (ATNM) Investor presentation summary

Investment thesis and financial position

• Pipeline spans solid tumors, hematology and conditioning, with several 2026 readouts and cash runway into 2028.

• Cash and equivalents were $36.5M at June 30, 2026; 31.4M shares outstanding, with no debt, warrants or preferred stock.

• In-house R&D, manufacturing buildout planned for 2H 2026, ~250 patents and proprietary Ac-225 production technology support development and supply.

Solid tumor pipeline

• ATNM-400 is a preclinical Ac-225 radiotherapy targeting an undisclosed target, with mCRPC, NSCLC and breast cancer as lead indications.

• Preclinical prostate models showed 87% tumor growth inhibition for ATNM-400 versus 0% for 177Lu-PSMA-617 in a low-PSMA model; presentation cites potential to address patients with low or no PSMA expression.

• In EGFR-mutant NSCLC models, ATNM-400 showed 3–5x greater tumor growth inhibition than approved therapies and 100% complete cures with osimertinib combination.

• Breast cancer models showed efficacy in trastuzumab-resistant and triple-negative settings, including reported tumor growth inhibition of 97% and 100% in combination arms.

• Actimab-A depletes CD33+ MDSCs; planned PD-1 combination trials target GBM and a basket of MDSC-rich tumors, with initial trial data expected in 2027.

Hematology and conditioning

• Actimab-A + CLAG-M is positioned as a mutation-agnostic AML backbone; FDA alignment is reported for a Phase 2/3 trial in relapsed/refractory AML, with a collaborator sought.

• In Phase 1b, Actimab-A + CLAG-M reported 80% MRD negativity and 18.4-month median OS in first/second-salvage patients; TP53-mutated patients had 83% MRD negativity and 9.6-month median OS.

• lomab-B is a Phase 2/3-ready CD45-targeted BMT conditioning asset; lomab-ACT is being studied in CAR-T and sickle cell disease conditioning trials, with initial proof-of-concept data expected in 2026.

• Planned 4Q 2026 milestones include initiating the Actimab-A + CLAG-M Phase 2/3 trial with a partner and a frontline AML triplet trial; CAR-T and sickle cell proof-of-concept data are targeted for 2027.